MicroRNAs in Lipid Metabolism and Atherosclerosis by Meiliana, Anna & Wijaya, Andi
 ͵
MicroRNAs in Lipid Metabolism and Atherosclerosis (Meiliana A)
Indones  Biomed J.  2014; 6(1): 3-16DOI: 10.18585/inabj.v6i1.39
 MicroRNAs in Lipid Metabolism and Atherosclerosis
Anna Meiliana1,2,, Andi Wijaya1,2
1Postgraduate Program in Clinical Biochemistry, Hasanuddin University, Jl. Perintis Kemerdekaan Km.10, Makassar, Indonesia
2Prodia Clinical Laboratory, Jl. Cisangkuy No.2, Bandung, Indonesia  
Corresponding author. E-mail: anna.meiliana@prodia.co.id
B
ACKGROUND: MicroRNAs (miRNA) are 
mediators of post-transcriptional gene expression 
that likely regulate most biological pathways and 
networks. The study of miRNAs is a rapidly emerging ield; 
recent indings have revealed a signiicant role for miRNAs 
in atherosclerosis and lipoprotein metabolism.
CONTENT: Results from recent studies demonstrated 
a role for miRNAs in endothelial integrity, macrophage 
inlammatory response to oxidized low-density lipoprotein, 
vascular smooth muscle cell proliferation and cholesterol 
synthesis. These mechanisms are all vital to the initiation and 
proliferation of atherosclerosis and cardiovascular disease. 
The importance of miRNAs has recently been recognized 
in cardiovascular sciences and miRNAs will likely become 
an integral part of our fundamental comprehension of 
atherosclerosis and lipoprotein metabolism. The extensive 
impact of miRNA mediated gene regulation and the 
relative ease of in vivo applicable modiications highlight 
the enormous potential of miRNA-based therapeutics in 
cardiovascular diseases.
SUMMARY: miRNA studies in the ield of lipid metabolism 
and atherosclerosis are in their infancy, and thus there is 
tremendous opportunity for discovery in this understudied 
area. The ability to target miRNAs in vivo through delivery 
of miRNA-mimics to enhance miRNA function, or anti-
miRNAs which inhibit miRNAs, has opened new avenues 
for the development of therapeutics for dyslipidemias and 
atherosclerosis, offers a unique approach to treating disease 
by modulating entire biological pathways. These exciting 
indings support the development of miRNA antagonists as 
potential therapeutics for the treatment of dyslipidaemia, 
atherosclerosis and related metabolic diseases.
L
ATAR BELAKANG: MicroRNAs (miRNA) 
merupakan mediator ekspresi gen pasca transkripsi 
yang mengatur hampir seluruh jalur dan jaringan 
biologis. Penelitian mengenai miRNA berkembang pesat; 
penemuan terbaru menunjukkan peran signiikan miRNA 
pada aterosklerosis dan metabolisme lipoprotein.
ISI: Hasil penelitian terkini menunjukkan peran miRNA 
pada integritas endotel, respon inlamasi makrofag terhadap 
oxidized low-density lipoprotein, proliferasi sel otot polos 
vaskular, dan sintesis kolesterol. Semua mekanisme tersebut 
berperan penting pada inisiasi dan proliferasi aterosklerosis 
dan penyakit kardiovaskular. Kesadaran akan pentingnya 
miRNA bagi ilmu kardiovaskular tampaknya akan 
menjadikan miRNA sebagai bagian tak terpisahkan dari 
perkembangan fundamental aterosklerosis dan metabolisme 
lipoprotein. Efek miRNA yang luas dalam memediasi 
regulasi gen serta relatif mudahnya modiikasi pada aplikasi 
in vivo menonjolkan potensi besar terapi berbasis miRNA 
pada penyakit kardiovaskular.
RINGKASAN: Penelitian mengenai miRNA pada 
metabolisme lemak dan aterosklerosis masih berada 
pada tahap dini, sehingga kesempatan untuk penemuan-
penemuan di bidang ini masih terbuka luas. Kemampuan 
menjadikan miRNA sebagai sasaran terapi secara in vivo 
melalui pemberian miRNA-mimics (tiruan miRNA) yang 
dapat meningkatkan fungsi miRNA, atau anti-miRNA yang 
dapat menghambat miRNA, telah membuka kesempatan 
baru perkembangan terapi dislipidemi dan aterosklerosis, 
menawarkan pendekatan yang unik untuk mengelola 
penyakit melalui modulasi jalur biologis secara keseluruhan. 
Penemuan yang menarik ini mendukung perkembangan 
antagonis miRNA sebagai terapi potensial untuk pengobatan 
dislipidemia, aterosklerosis dan penyakit metabolisme.
Abstract Abstrak
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Mendelian randomization studies have shown that certain 
single-nucleotide polymorphisms that raise plasma high-
density lipoprotein cholesterol (HDL-C) levels do not 
lower the risk of myocardial infarction, challenging the 
concept that HDL is atheroprotective.(1)  Compounding 
these indings, several clinical trials of HDL-C-raising 
therapeutics, including niacin and inhibitors of cholesterol 
ester transfer protein (CETP), have failed to show beneit.
(2,3) These studies have begun to cast doubt on HDL’s 
atheroprotective functions and spurred further investigations 
of the molecular mechanisms regulating levels of plasma 
HDL and its function. One area of rapid growth in this regard 
has been the discovery of microRNAs (miRNAs) as potent 
regulators of the gene pathways controlling HDL genesis, 
cholesterol eflux, and reverse cholesterol transport (RCT).
 Over 1,500 human miRNAs have been curated in 
miRBase (miRBase.org), and each cell type typically 
contains a speciic subset of approximately 150-300 
miRNAs. One miRNA can target and regulate potentially 
hundreds of genes (mRNAs) through seed-based targeting, 
and one gene (mRNA) can be under negative repression 
of more than one miRNA. The nature of miRNA gene 
repression is, therefore, complex and highly interconnected 
with both direct and indirect effects. Nonetheless, miRNA 
networks modulate many aspects of cellular homeostasis 
and physiology and thus are a promising new area of 
investigation.(4)
 For the past decade, the importance of noncoding 
RNA as regulators of pre-, co-, and post-transcriptional 
gene expression has emerged.(5) Of the various classes of 
noncoding RNAs, miRNAs are currently the most widely 
studied and have established roles in regulating a myriad 
of biological processes.(6) Although miRNAs likely play a 
role in most homeostatic pathways, they also appear to be 
powerful regulators in the development of various diseases. 
Dysregulation or altered miRNA expression/function has 
been implicated in diabetes (7), cardiovascular disease (8-
12), and numerous types of cancers. The role of miRNAs 
as biomarkers has also gained signiicant attention in 
both academic research labs and in vitro diagnostic test 
companies. miRNAs are stable in plasma and differential 
plasma miRNA proiles have been described for many 
Introduction
diseases, including fatty liver (13), atherosclerosis (14-16), 
and cancer (17-21). Circulating miRNAs have enormous 
potential as novel disease biomarkers; however, circulating 
extracellular miRNAs may also be biologically active.
 Most of the novel miRNA-mediated regulatory 
mechanisms associated with atherosclerosis and lipoprotein 
metabolism to date have irst been determined by 
miRNA proiling, followed by functional testing.(22,23) 
The discovery of miRNA gene regulatory mechanisms 
contributing to endothelial integrity, macrophage 
inlammatory response to atherogenic lipids, vascular 
smooth muscle-cell proliferation, and cholesterol synthesis. 
At this time, the applicability and full potential of miRNAs 
in clinical practice is unknown. Nonetheless, recent 
advances in miRNA delivery and inhibition hold great 
promise of a tremendous clinical impact in atherosclerosis 
and cholesterol regulation.(11)
miRNAs are a speciic class of noncoding RNA (ncRNA), 
and are deined as small, 20-22 nucleotide RNA molecules 
that are processed from a much larger primary transcript. 
Once processed into their mature form, miRNAs generally 
bind to complimentary sequences in the 3′ untranslated 
region (UTR) of speciic genes but can also bind to other 
regions of the gene including the 5′ UTR and the coding 
region.(24,25) Via mRNA destabilization and/or protein 
translation inhibition, miRNAs mediate silencing of their 
bound targets.
 miRNAs have diverse expression patterns and might 
regulate various developmental and physiological processes. 
Their discovery adds a new dimension to our understanding 
of complex gene regulatory networks.(26) Two processing 
events lead to mature miRNA formation in animals. In 
the irst, the nascent miRNA transcripts (pri-miRNA) are 
processed into ~70-nucleotide precursors (pre-miRNA); in 
the second event that follows, this precursor is cleaved to 
generate ~21-25-nucleotide mature miRNAs.(27)
 The impact of miRNAs on the proteome indicated that 
for most interactions of miRNAs act as rheostats to make 
ine-scale adjustments to protein output.(28) Studies show 
that a single miRNA can directly downregulate production 
of hundreds of proteins. In addition to the known effect 
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on global mRNA levels (29), data strongly indicate that 
miRNAs translationally repress hundreds of direct target 
genes (30). miRNAs are involved in a plethora of important 
biological processes, from embryonic development to 
homeostasis in adult tissues. Recently, miRNAs have 
emerged as a class of epigenetic regulators of metabolism 
and energy homeostasis.(31)
 Because of their size, abundance, tissue speciicity, and 
relative stability in plasma, miRNAs hold promise as unique 
accessible biomarkers to monitor tissue injury. miRNAs have 
been found to be involved in almost every biological process, 
from cellular differentiation and proliferation (32,33) to cell 
death and apoptosis (34,35), from synaptic plasticity (36) 
to immunity (37) and cardiovascular development (38); in 
addition, changes in miRNA levels and activity have been 
linked to human pathologies, including cancer (39) and 
cardiovascular diseases (40,41). miRNAs can regulate the 
mRNA levels of their targets (29,42), and pharmacological 
silencing of miRNAs using antagomirs might therefore lead 
to the regulation of many mRNAs.(31)
 Eficient silencing of miRNA-122 (miR-122) was 
achieved in primates by three doses of 10 mg/kg locked-
nucleic-acid (LNA)-anti-miR, leading to a long-lasting and 
reversible decrease in total plasma cholesterol without any 
evidence for LNA-associated toxicities or histopathological 
changes in the study animals.(43)
Until recently, the predominant view of intercellular 
communication was that it was limited to cell-to-cell 
adhesion conduits (gap junctions) or secreted signals, 
such as hormones and neurotransmitters. New studies 
have revealed that plasma-membrane-derived vesicles, 
namely exosomes and microvesicles, can transfer proteins, 
mRNAs and miRNAs from donor cells to recipient cells.
(44-47) miRNAs are short non-coding regulatory RNAs 
that modulate biological homeostasis by controlling gene 
expression through mRNA targeting and translational 
repression.(28,30,48,49) Circulating miRNAs are a 
new class of biomarkers and have recently been used 
for a diverse set of diseases. We now understand that the 
secretion of miRNAs is a controlled, active, and speciic 
process. miRNAs can be packaged into lipid-based carriers 
such as exosomes, microparticles, or apoptotic bodies, and 
have been found on lipoproteins like high- and low-density 
lipoprotein (HDL and LDL, respectively). Additionally, 
a signiicant portion of extracellular miRNAs are found 
without a lipid carrier, and are protein-bound. While the 
mechanisms of the selectivity of miRNA packaging remain 
unclear, researchers are beginning to unravel some of the 
mysteries surrounding how these tiny RNA molecules make 
their way out of the cell.(50)
 The complexity of miRNA-mediated pathway control 
has burgeoned since the discovery that miRNAs are found 
in the extracellular space and constitute a form of cell-cell 
communication. miRNAs have been found in plasma, urine, 
and saliva and have recently been shown to be carried on 
lipoproteins. This has led to the proposal that circulating 
miRNAs may be useful biomarkers of various diseases, 
including cardiovascular disease, diabetes, and other forms 
of dysregulated metabolism.(50)
 Given the lability of most RNAs, it is perhaps 
surprising that circulating miRNAs in plasma are relatively 
stable and appear to be resistant to plasma ribonucleases 
(RNase).(51) This protection has been shown to be 
conferred by their lipid-based carriers that shield the small 
RNAs from plasma RNases.(51-54) Circulating miRNAs 
themselves are not inherently resistant to degradation.(55) 
Once their lipid-based carriers are disrupted, either by the 
addition of detergents (56) or by sonication (57), they are 
sensitive to RNase degradation. The most widely studied 
lipid-based miRNA carriers are exosomes, which are 
membrane-derived vesicles that originate from endosomal 
multivesicular bodies.(52,58,59) Exosomes, which are 
derived from intracellular vesicles of approximately 100nm 
in diameter, have a similar size range of 40–100nm when 
released into the interstitial luid.(60) The external release 
of exosomes by the fusion of multivesicular endosomes 
with the plasma membrane is a distinct process that is not 
shared by other membrane-derived vesicles.
 In addition to exosomes, other membrane-bound 
and lipid-containing vesicles transport miRNA in the 
extracellular space. Microvesicles are larger than exosomes, 
typically ranging from 100 nm to 1 μm in size, with most 
microvesicle preparations comprised of a heterogeneous 
mixture of particles.(61) Microvesicles are secreted 
by a number of different cell types, including vascular 
cells, platelets, and inlammatory cells, and it has been 
speculated that almost all cell types are capable of secreting 
microvesicles under speciic conditions.(62) Apoptotic 
bodies are another variety of lipid-encapsulated vesicles 
known to carry miRNA. These types of vesicles are 
generally much larger (~500 nm to >2,000 nm) and have a 
heterogeneous size distribution.(63) As the name suggests, 
apoptotic bodies are released at the early stages of apoptosis, 
and contain both a lipid bilayer derived from the plasma 
membrane and cytoplasmic contents that originate from the 
parent cell.
Lipid-based Carrier of miRNA and 
Intercellular Communication
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 In addition to lipid-encapsulated organelles released 
from cells, lipoproteins have also been shown to associate 
with miRNA and are arguably the most important lipid 
carrier in the body. Lipoproteins are comprised of various 
proteins and lipids and are responsible for the delivery 
of cholesterol, triacylglycerols, steroids, and fat-soluble 
vitamins to peripheral tissues from the liver via LDL and 
removal from peripheral tissues to the liver/digestive 
system via HDL.(64,65) Due to their inherent solubility 
and their tendency to trap water-insoluble material in their 
core, lipoproteins have demonstrated an ability to carry 
nucleic acids and are often used as gene delivery agents, 
and it has been demonstrated in a recent study that different 
RNA structures display varying afinities for phospholipid 
membranes and this could affect the ability of an RNA 
molecule to bind to a lipoprotein.(4,46)
 Vickers et al. (4) were the irst to demonstrate that 
human HDL and LDL have the capability to carry miRNAs 
in the core of the molecule hidden from the extracellular 
environment in serum, and most importantly these miRNAs 
can be transferred to recipient cells and alter target cell 
gene expression. Importantly, this study revealed, at least 
in the case of HDL, that the miRNAs carried in these 
lipoproteins differ between healthy subjects and those with 
atherosclerotic vessel disease. One of the most abundant 
miRNAs detected in HDL particles was miR-223 which, 
intriguingly, was found to be highly enriched in monocytes/
macrophages.(46) These data suggest that it may be 
peripheral cells like macrophages that may be off-loading 
their miRNA into HDL particles, and not necessarily the 
cells responsible for HDL biogenesis. HDL-miRNAs could 
potentially serve as diagnostic markers in much the same 
way that exosome miRNAs have been used.(66-70). HDL 
could simply be a depot or carrier for circulating miRNAs 
and their presence in HDL may not necessarily relate to the 
function of HDL in atherosclerosis or lipid metabolism. If 
so, miRNAs in HDL could perhaps be used diagnostically 
for a wide variety of diseases besides atherosclerosis.(71) 
 Argonaute proteins (Ago1/2), which act as effector 
molecules for miRNAs, are detected in cell supernatants 
and are not necessarily associated with vesicles of any 
kind (microvesicles or exosomes).(72) The binding of 
Ago2 to miRNA protects the miRNA from degradation by 
the abundant amount of RNases found in plasma, and it is 
believed that Ago2 protein can assist in functional transfer 
of miRNAs that it carries.(55) Many different proteins and 
pathways have been linked to exosome export, including the 
ceramide pathway. Ceramide has been shown to facilitate 
the formation of endosomal vesicles (73), and the export of 
speciic miRNAs to exosomes (74). Knockdown of neutral 
Figure 1.  MicroRNAs are secreted into the circulation and are biomarkers for various diseases. (50) (Adapted with permission from 
American Society for Biochemistry and Molecular Biology).
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sphingomyelinase 2 (nSMase2), the key enzyme in ceramide 
synthesis, with siRNAs leads to a decrease in the cellular 
export of miR-16 and miR-146a.(52) Less is even known 
about the cellular uptake of miRNAs than their export, but 
there are two main hypotheses. For vesicles (microvesicle/
exosomes) containing miRNAs, it has been proposed that 
they are delivered to cells either by a process involving 
endocytosis (75,76) or by membrane fusion (77,78). Surface 
or transmembrane proteins on vesicles and/or cell surface 
receptors likely contribute to the initial recognition of target 
cells; however, the identity of these cell surface receptors or 
their ligands is unknown.
 Scavenger receptor class B type I (SR-BI) mediates 
the uptake of miRNAs associated with HDL.(71) Because 
the selective core uptake of lipids on HDL by SR-BI also 
bypasses the endosomal–lysosomal pathway (79,80), 
delivery of miRNAs by this pathway may also lead to 
less degradation of miRNAs. We are only beginning to 
understand the physiologic impact of miRNA intercellular 
communication, but many studies have now shown that this 
process leads to gene expression changes in recipient cells. 
(81-83)
 Circulating miRNAs can be associated with a variety 
of lipid-based vesicles and lipoproteins, as well as with 
lipid-free protein complexes. The physiological relevance of 
miRNA intercellular communication to wellness or disease 
remains to be determined; however, circulating miRNAs 
show great promise as novel disease biomarkers and may 
lead to new diagnostic tests. The excitement for miRNAs 
as biomarkers is mounting as more and more evidence 
supports that these noncoding RNAs are actively secreted 
from diseased tissues, possibly before the onset of overt 
disease. Circulating miRNAs may also represent a new way 
to intervene therapeutically in treating a wide variety of 
diseases and in better understanding gene regulation.(4)
The primary functions of lipoproteins are the delivery of 
neutral lipids, such as triglycerides, and to a lesser degree 
cholesterol to peripheral cells and the removal of excess 
Figure 2.  miRNA coordination of HDL homeostasis.(6) miRNAs have been shown to regulate genes involved in cholesterol eflux 
and HDL homeostasis in various tissues, including the liver, intestine, and macrophage (Adapted with permission from American Heart 
Association).
miRNA and Lipoprotein Metabolism
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cellular cholesterol by the reverse cholesterol transport 
pathway.(84) The epicenter of lipoprotein metabolism 
resides in the liver, which has been the focus of many miRNA 
studies.(85-87) Insuficient or excessive cellular cholesterol 
results in pathologic processes including atherosclerosis and 
metabolic syndrome.(88-91) The mechanisms controlling 
this balance remain incompletely understood (92).
 Many diseases result from perturbations in lipid 
homeostasis, including atherosclerosis, type II diabetes 
and metabolic syndrome.(88-90,93) The intracellular and 
membrane levels of fatty acids and cholesterol are under 
constant surveillance and are coordinated with de novo lipid 
biosynthesis by endoplasmic reticulum (ER)-bound sterol 
regulatory element-binding proteins (SREBPs).(94-96)
 Lipid metabolism is tightly regulated at the cellular 
level. In addition to classic transcriptional regulation 
of cholesterol metabolism (e.g. by SREBP and liver X 
receptor (LXR)), miRNAs have now been identiied to be 
potent post-transcriptional regulators of lipid metabolism 
genes involved in cholesterol homeostasis and fatty acid 
oxidation.(92) Recent discoveries of miRNAs that control 
high-density lipoprotein abundance and function have 
expanded our knowledge of the mechanisms regulating 
this important lipoprotein subclass. miRNAs have been 
shown to regulate gene networks that control high-density 
lipoprotein biogenesis and uptake, as well as discrete steps 
in the reverse cholesterol transport pathway.(6)
 Nascent HDL is generated in the liver through the 
eflux of cholesterol and phospholipid across the hepatocyte 
membrane onto newly synthesized lipid-poor apolipoprotein 
A-I.3 The ATP-binding cassette transporter A1 (ABCA1) 
plays a critical role in this process as evidenced by the near-
absence of plasma HDL-C in patients with Tangier disease, 
which results from mutations in the ABCA1 gene.(97-100) 
The levels of ABCA1 at the plasma membrane controls 
the rate of cholesterol eflux to apolipoprotein A-I, and 
hepatic-speciic deletion of ABCA1 results in an ≈85% loss 
of total HDL-C, with ABCA1 in the adipose and intestine 
contributing to the residual balance.(101-105)
 Several miRNAs have recently been identiied that 
target ABCA1 and thus regulate plasma levels of HDL-C. 
Among these, miR-33a and miR-33b were the irst to be 
reported (106,107) and were intriguing because of their 
genomic context: miR-33a and miR-33b are embedded in 
intronic regions of SREBP2 and SREBP1 genes that code 
for the SREBP2 and SREBP1 transcription factors that 
control the expression of genes involved in cholesterol and 
fatty acid synthesis. MiR-33a/miR-33b are coregulated 
with their host genes and act to repress gene programs that 
oppose SREBP functions.
 The physiological relevance of miR-33 targeting of 
ABCA1 was initially demonstrated using inhibitors of miR-
33, which increased cholesterol eflux from hepatocytes 
to apolipoprotein A-I in vitro and raised levels of plasma 
HDL-C in mice by 25% to 30%. These indings were 
subsequently conirmed by targeted deletion of miR-33, 
which resulted in 25% and 40% increases in plasma HDL-C 
in male and female miR-33 null mice, respectively (108).
 Indeed, shortly after the discovery of miR-33, other 
miRNAs were found to repress ABCA1 and cholesterol 
eflux in vitro, including miR-758 (109), miR-26 (110) and 
miR-106b (111). Recently, 2 groups reported that miR-144, 
an intergenic miRNA present in a bicistronic cluster with 
miR-451, also targets ABCA1 in the liver and modulates 
plasma HDL-C levels.(112,113) Interestingly, miR-
144 expression is regulated by 2 members of the nuclear 
hormone receptor family: the farsenoid X receptor and LXR 
(112,113), providing ine-tuning of ABCA1 expression 
under speciic biological contexts.
 Collectively, the studies of miR-33 and miR-144 
have begun to illuminate the intricate network that ine-
tunes ABCA1-dependent cholesterol eflux from the liver 
to regulate plasma HDL-C. It is likely that numerous other 
miRNAs will be identiied to act in concert to regulate 
ABCA1 expression in the liver, with their individual and 
combined contributions determined by factors that regulate 
miRNA expression and abundance. The identiication of such 
metabolic rheostats will no doubt provide new opportunities 
for therapeutic manipulation of plasma HDL-C levels and 
RCT. The eflux of excess cholesterol from peripheral tissues, 
particularly macrophages in the artery wall (102,104), is 
essential for maintaining cholesterol homeostasis. At the 
cellular level, this requires that cholesterol irst be mobilized 
from internal stores via cooperation of the lysosome, 
lipid droplets, neutral cholesteryl ester hydrolase, and the 
autophagy machinery.(114) The inal step of cholesterol 
eflux from the plasma membrane is mediated by ABCA1 
to lipid-poor apolipoprotein A-I (ApoE in the brain) and 
through the related transporter, ABCG1, to mature HDL 
particles.
 Autophagy, which regulates the availability of free 
cholesterol for eflux (115-118) and contributes prominently 
to macrophage RCT in vivo, is a complex process that requires 
multiple sequential membrane remodeling and traficking 
events, orchestrated by a small army of autophagy-related 
gene (ATG) proteins. This pathway has recently been shown 
to be regulated by several miRNAs, including miR-18a, 
miR- 20a, miR-30a, miR-30d, miR-101, miR-106b, miR-
132, miR-181a, miR-196, miR-212, miR-221, miR-222, 
miR-376b, miR-502 (119-127), which act by targeting ATG 
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proteins (ATG2, ATG4, ATG5 and ATG12) (14,113,114,127) 
or their upstream effectors (Beclin 1 (BECN1), mammalian 
target of rapamycin (mTOR) and uncoordinated 51-like 
kinase 1 (ULK1).(120,122,123,125,127)
 Like miR-33, miR-26 also downregulates other 
genes involved in cholesterol mobilization in addition 
to ABCA1, such as ADP ribosylation factor-like 7, an 
intracellular transport protein that moves cholesterol to 
the membrane for removal by ABCA1.(110) Expression of 
miR-26 is suppressed by LXR and thus would be predicted 
to be downregulated under conditions of cholesterol 
excess during which increased levels of ABCA1 would 
be needed. However, miR-144 would be induced by LXR 
to target ABCA1 under similar conditions (112), and thus 
further studies of the temporal expression and abundance 
of these 2 miRNAs will be needed to resolve their relative 
contribution to cholesterol eflux control. Finally, miR-758 
and miR-106b have been found to be highly enriched in the 
brain where ABCA1 plays a key role in efluxing excess 
cholesterol to ApoE, the predominant apolipoprotein in the 
brain (111,128).
 Transport of HDL-C to the liver for bile acid synthesis 
and excretion is the inal step of RCT and can occur either 
directly via SR-BI or after transfer to apolipoprotein B–
containing lipoproteins by the CETP present in humans. 
miRNAs targeting these pathways are just beginning to be 
explored and represent exciting new therapeutic targets to 
inluence the route of delivery of HDL’s cargo (6).
 Bioinformatic prediction algorithms, such as 
Targetscan and MiRanda, indicate that ≤50 miRNAs may 
target the 3′UTR of human SR-BI. Among these, miR-185, 
miR-96, and miR-223 were validated as strong repressors 
of SR-BI mRNA and cell surface expression, and their 
inhibition in HEPG2 cells increased SR-BI expression and 
selective HDL-C uptake.(129) In addition to its critical role 
in RCT, HDL can exert antiinlammatory, antioxidant, and 
antithrombotic effects, and these functions seem to vary 
among individuals. It is thus possible that these functions of 
HDL may be mediated in part by, or altered by, the subset of 
miRNAs that it carries. Indeed, the miRNA cargo of HDL 
has been shown to be altered in both mice and humans by 
hypercholesterolemia and atherosclerosis.(71)
 miRNA-based therapeutics represent a new class of 
drugs that hold promise for the treatment of cardiovascular 
and other diseases. The recent Food and Drug Administration 
approval of Kynamro (previously known as Mipomersen), 
a irst-inclass antisense oligonucleotide inhibitor that targets 
apolipoprotein B-100 to reduce LDL cholesterol for the 
treatment of homozygous familial hypercholesterolemia, 
represents a giant leap forward for oligonucleotide-
based therapies, including miRNA therapeutics.(130) 
These results have generated considerable excitement for 
the possibility of using miRNA-based therapies to treat 
cardiovascular disorders. miR-33 inhibition is thought to be 
particularly promising as a therapeutic for atherosclerosis 
because it would enhance multiple components of the RCT 
pathway, including HDL biogenesis, cholesterol eflux from 
plaque macrophages, and cholesterol excretion to the bile. 
Indeed preclinical studies of miR-33 inhibition in mice 
and nonhuman primates for ≤12 weeks showed sustained 
increases in HDL-C (on the order of 40-50%).(12) 
 The prospect that HDL-carried miRNAs contribute 
to the heterogeneous effects of HDL on endothelial cells, 
macrophages, and other cell types that inluence vascular 
health is intriguing and may provide insight into how the 
protective effects of HDL may be altered in disease or 
enhanced for therapeutic purposes (6).
Atherosclerosis is a multifactorial disease driven, in 
part, by chronic inlammation in response to cholesterol 
accumulation in the arterial wall.(131) The irst major 
event in the progression of the early atheroma is the 
loss of endothelial integrity. Endothelium dysfunction 
facilitates the subendothelial accumulation of cholesterol-
bearing lipoproteins, compromises vasodilation, and is 
both proinlammatory and prothrombotic.(132,133) A 
majority of what we understand about the role of miRNAs 
in endothelial cells comes from studies of angiogenesis. 
Endothelial migration studies, utilizing wound healing 
assays, revealed a signiicant role for let-7, miR-221, and 
miR-222 in endothelial function.(134-137) Furthermore, 
recent studies have shown that miR-92a prohibits 
angiogenesis, whereas miR-126 sustains vascular integrity 
and promotes angiogenic signaling.(138,139)
 Atheroprotective stimuli induce communication 
between endothelial cells and smooth muscle cells (SMCs) 
through an miRNA- and extracellular-vesicle-mediated 
mechanism and that this may comprise a promising strategy 
to combat atherosclerosis.(140) Circulating endothelial 
progenitor cells (EPCs) have been demonstrated to play 
an integral role in endothelial integrity due to their ability 
to reinforce the endothelium with new healthy endothelial 
cells to replace damaged or apoptotic cells.(141,142) In a 
recent study, individuals with atherosclerosis, as deined by 
coronary artery disease (CAD), showed signiicantly higher 
expression of miR-221 and miR-222 in EPCs compared with 
non-CAD individuals.(143) Furthermore, miR-221/222 
miRNA and Atherosclerosis
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levels were observed to be inversely related to EPCs levels, 
as CAD individuals had signiicantly less EPCs numbers.
 miR-126 was shown to provide an atheroprotective 
effect (144) and was reported to be upregulated by low in 
a klf2-dependent manner in zebraish embryos.(145) The 
shear-sensitive miR-19a contributes to the antiproliferative 
effect of shear low (146), whereas miR-10a regulation 
is involved in the antiinlammatory properties of shear 
stress.(147) miRNAs also regulate SMCs functions, and 
in particular, the cluster comprising miR-143 and miR-145 
has been described to be of crucial importance for proper 
SMCs function.(148-150)
 Recent observations of miRNA proile changes in 
balloon-injury and carotid-ligation models have revealed 
dynamic lux of speciic miRNAs in the arterial wall, as part 
of the larger proliferative response.(22,148) Speciically, 
miR-125a, miR-125b, miR-133, miR-143, miR-145, miR-
365 appear to be downregulated, and miR-21, miR-146, 
miR-214, and miR-352 were observed to be upregulated 
in neointimal formation models.(22) Accordingly, these 
observations have led to loss of function knockdown 
experiments, demonstrating that miR-21 promotes 
proliferation and neointimal growth due to injury.(22,151)
 The role of miRNAs in VSMCs proliferation has been 
extensively but not exhaustively investigated.(150,152-
155) Recently, miR-145 has been demonstrated to be a 
key determinant in VSMCs differentiation and phenotype 
(156,157) and to be downregulated in both atherosclerosis 
and arterial-injury models.(22,148) Together with miR-
145, miR-143 has recently been shown to regulate the 
VSMCs proliferative response to balloon-injury through 
alterations in cytoskeleton organization.(156) Moreover, 
miR-92a seemed to be highly speciic for the atherosclerotic 
endothelium: macrophages and SMCs that were exposed to 
oxidized LDL (oxLDL) expressed miR-92a only at a low 
level.(157)
 Loyer et al. have discovered an additional feature 
of miR-92, which is relevant to atherosclerosis: miR-
92a expression is mediated by oxLDL. When endothelial 
cells were exposed to oxLDL and low shear stress, Loyer 
et al. found that they secreted interleukin-6 and monocyte 
chemoattractant protein-1, which could be reversed by 
inhibition of miR-92a. The expression of miR-92a in the 
endothelial cells of atherosclerosis prone areas seemed to 
be driven by signal transducer and activator of transcription 
3 (STAT3).(158) These combined regulatory effects of 
miR-92a in endothelial activation make it thus an important 
regulator of atherosclerosis development.
 The potential of miR-92a to be used both as a diagnostic 
and therapeutic target in atherosclerotic disease. Because 
this miRNA seems to particularly act on the endothelium 
in atherosclerosis-prone areas, both systemic and local 
therapeutic approaches using miRNA inhibitors could be 
of interest in both preventing atherosclerotic disease and 
minimizing tissue loss on infarction when atherosclerotic 
disease is irreversible.(157)
miRNA proiling can provide additional information about 
the biological processes involved in atherosclerosis, but 
miRNAs have also been thought to be potential biomarkers 
and drug targets. Circulating miRNAs have many qualities 
that make them attractive candidate molecular biomarkers. 
They are stable and evolutionarily conserved, and the 
changes in their expression are often tissue or disease 
speciic. They are found in many body luids such as urine, 
plasma, serum, and cerebrospinal luid.(159)
 Prognostic and diagnostic value for circulating 
miRNAs in ischemic cardiac disease has been investigated 
in several up-to-date publications.(160-162) The use of 
high-sensitive realtime/quantivative PCR (Q-PCR) or array 
technique facilitates miRNAs detection in body luids, 
even if miRNAs are present at very low concentration in 
the circulation. There are likely two classes of miRNA 
biomarkers: 1) those miRNAs secreted passively due to 
tissue stress, injury, or necrosis, and therefore may not 
relect the biology associated with disease pathogenesis; 
and 2) those miRNAs actively and/or chronically secreted 
during disease progression and perhaps contribute to the 
pathogenesis. An example of the former comes from the 
identiication of myocardium-derived miRNAs in the 
circulation following a myocardial infarction. miR-208 and 
miR-499 are muscle-speciic miRNAs and were the irst to 
be identiied in the circulation of patients following an acute 
myocardial infarction (AMI) (163). De Rosa et al. (10) went 
on to show that in conjunction with miR-208 and miR-499, 
miR-133 is also found in the serum of patients suffering 
from an AMI, and that these miRNAs are indeed derived 
from the myocardium. 
 The implications of miRNAs in the pathological process 
of the cardiovascular system have been recognized recently, 
and research on miRNAs in relation to cardiovascular 
disease has become a rapidly evolving ield.(108,164) It is 
known that miR-1, miR-133a, miR-133b, miR-206, miR-
208a, miR-208b, and miR-499 are muscle-speciic miRNAs. 
Among them, miR-133b and miR-206 are expressed only in 
miRNA: Therapeutics and Diagnostics 
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Conclusion
It is clear that the potential of extracellular miRNA for use 
as both a diagnostic and a therapeutic tool is tremendous, 
and in the span of a few years, the i eld has turned from 
skepticism to acceptance that these tiny nucleic acids might 
be playing a role in the extracellular space. Undoubtedly 
an improved understanding of miRNA export and uptake 
will aid in the therapeutic arena, and will greatly assist the 
tailoring of individual miRNA therapies for speciic diseases 
and tissues and hopefully aid in the eradication of possibly 
preventable diseases like dyslipidemia and atherosclerosis.
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